Home > Riviste > Journal of Neurosurgical Sciences > Fascicoli precedenti > Journal of Neurosurgical Sciences 2020 June;64(3) > Journal of Neurosurgical Sciences 2020 June;64(3):258-62

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2020 June;64(3):258-62

DOI: 10.23736/S0390-5616.19.04839-2

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Supplementary management with Pycnogenol® in Parkinson’s disease to prevent cognitive impairment

Maria R. CESARONE 1, 2, Gianni BELCARO 1, 2 , Morio HOSOI 1, 2, Andrea LEDDA 1, 2, Beatrice FERAGALLI 2, Claudia MAIONE 1, Claudia SCIPIONE 1, Valeria SCIPIONE 1, Roberto COTELLESE 2, Shuh HU 1, 2

1 Irvine3 Labs & San Valentino Vascular Screening Project, Chieti, Italy; 2 Department of Medical Oral Biotechnology Sciences, D’Annunzio University, IA-PSS (International Agency for Pharma-Standard Supplements), Pescara, Italy



BACKGROUND: The aim of this registry study in patients with Parkinson’s Disease (PD) in treatment, was to evaluate the effects of Pycnogenol® supplementation on some accessory symptoms and cognitive functions (COFU).
METHODS: The registry included 43 PD patients who had been diagnosed at least one year before the start of the study. The PD condition was considered mild, with minimal progression. The management for these patients was a monotherapy using carbidopa/levodopa (standard management; SM). Supplementary Pycnogenol® was used at 150 mg/day for 4 weeks. The neurological management was not affected.
RESULTS: Tolerability and safety were very good; the two registry groups were comparable with comparable symptoms at baseline. The most disabling symptoms were considered tremor, bradychinesia, alterations in COFU, rigidity and speech changes. All symptoms were rated as mild-to-moderate. After 4 weeks, these target symptoms were significantly attenuated with the supplement in comparison with the SM only (P<0.05). Particularly the COFU score was significantly higher (P<0.05) with the supplement. No interference between the main neurological management and the supplement was observed. Oxidative stress (plasma free radicals), high in both registry groups at inclusion, was significantly lower in the supplement group at 4 weeks (P<0.05). The main PD-associated items (cognitive aspects, motory and postural aspects) considered the most common and disturbing problems were evaluated and scored (0 to 4) with a visual scale line. At 4 weeks, the scores for all items were lower in the supplement group in comparison with the control, SM group. Peripheral edema was present in all patients at inclusion. The edema was minimal at inclusion (at the ankle-foot level with pretibial extension) and present in all subjects. It changed in two SM subjects and was still present at 4 weeks in 19 out 22 of the SM patients. In the supplemented patients, edema (present at inclusion in all subjects), was visible in 4 subjects out of 21 (19%) at 4 weeks.
CONCLUSIONS: Pycnogenol® supplementation may help in selected patients with PD - under stable neurological treatment - to improve some signs and symptoms and some aspects associated with COFU. Studies are in progress on a larger population sample and with new evaluation methods.


KEY WORDS: Parkinson disease; Cognitive dysfunction; Pycnogenols; Oxidative stress

inizio pagina